Phase 3 data of mdc-IRM first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia
15 November 2021
Phase 3 data of mdc-IRM, first product based on MedinCell’s […]
Our news
Bringing you the latest!
Corporate
MedinCell: mdc-IRM’s Phase 3 data to be presented for the first time by Teva at Psych Congress 2021
21 October 2021
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
31 August 2021
Participation terms in the MedinCell Combined General Meeting
4 August 2021
MedinCell announces the availability of its 2020/2021 Universal Registration Document including the Annual Financial Report
28 July 2021
MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development
14 June 2021
Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin
19 April 2021